Breast Cancer
Evidence-based overview of mebendazole in breast cancer, including HIF suppression, stem-like-cell effects, and hypoxia-related biology
Mebendazole has important mechanistic relevance in breast cancer, especially around hypoxia, HIF signalling, and aggressive or stem-like tumour behaviour.
Overview
The breast-cancer evidence centres on HIF inhibition, AKT and STAT3-related biology, and reduced stem-like features, especially in triple-negative contexts.
Key findings
Mebendazole disrupts HIF transcriptional activity in breast cancer cells
Suppresses BCL-2, AKT, and STAT3-linked survival signalling
May reduce stem-like properties in triple-negative models
Broad ERK/MAPK-related significance is also relevant in aggressive subtypes
Clinical positioning
This is still preclinical, but the HIF and hypoxia angle makes it especially interesting in aggressive breast-cancer biology.
References
Mebendazole Treatment Disrupts the Transcriptional Activity of HIFs in Breast Cancer
https://pmc.ncbi.nlm.nih.gov/articles/PMC9954103/
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.